Cargando…

Coronavirus Disease 2019 or Lung Cancer: What Should We Treat?

Detalles Bibliográficos
Autores principales:	Russano, Marco, Citarella, Fabrizio, Vincenzi, Bruno, Tonini, Giuseppe, Santini, Daniele
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	International Association for the Study of Lung Cancer. Published by Elsevier Inc. 2020
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7151236/ https://www.ncbi.nlm.nih.gov/pubmed/32283315 http://dx.doi.org/10.1016/j.jtho.2020.04.001

Ejemplares similares

Response to: Successful afatinib rechallenge in a patient with non‐small cell lung cancer harboring EGFR G719C and S768I mutations
por: Citarella, Fabrizio, et al.
Publicado: (2021)

Cabozantinib and apixaban: an hitherto unreported interaction
por: Santini, Daniele, et al.
Publicado: (2019)

Facing SARS-CoV-2 outbreak in immunotherapy era
por: Citarella, Fabrizio, et al.
Publicado: (2020)

Steroid-refractory immune related hepatitis may hide viral re-activation
por: Citarella, Fabrizio, et al.
Publicado: (2020)

Change from lung adenocarcinoma to small cell lung cancer as a mechanism of resistance to afatinib
por: Manca, Paolo, et al.
Publicado: (2017)

Prognostic and predictive factors in pancreatic cancer
por: Dell’Aquila, Emanuela, et al.
Publicado: (2020)

Liquid biopsy and tumor heterogeneity in metastatic solid tumors: the potentiality of blood samples
por: Russano, Marco, et al.
Publicado: (2020)

Pazopanib and pancreatic toxicity: a case report
por: Russano, Marco, et al.
Publicado: (2015)

Correction to: Liquid biopsy and tumor heterogeneity in metastatic solid tumors: the potentiality of blood samples
por: Russano, Marco, et al.
Publicado: (2020)

Immunotherapy for Metastatic Non-Small Cell Lung Cancer: Therapeutic Advances and Biomarkers
por: Russano, Marco, et al.
Publicado: (2023)

Large-Scale Profiling of Extracellular Vesicles Identified miR-625-5p as a Novel Biomarker of Immunotherapy Response in Advanced Non-Small-Cell Lung Cancer Patients
por: Pantano, Francesco, et al.
Publicado: (2022)

First-line targeted therapies in the treatment of metastatic colorectal cancer – role of cetuximab
por: Tonini, Giuseppe, et al.
Publicado: (2009)

Coronavirus disease 2019 (COVID-19): What we need to know
por: Javanian, Mostafa, et al.
Publicado: (2020)

Rechallenge therapy and treatment holiday: different strategies in management of metastatic colorectal cancer
por: Tonini, Giuseppe, et al.
Publicado: (2013)

Serum VEGF levels as predictive marker of bisphosphonate-related osteonecrosis of the jaw
por: Vincenzi, Bruno, et al.
Publicado: (2012)

What special considerations should acute appendicitis bring to the clinician in the midst of Coronavirus Disease 2019
por: Yu, Xianqiang
Publicado: (2021)

Should we avoid colleagues in leisure time during the coronavirus disease 2019 (COVID-19) pandemic?
por: Oksanen, Lotta-Maria A. H., et al.
Publicado: (2020)

Multinational monkeypox outbreak: what do we know and what should we do?
por: Memariani, Mojtaba, et al.
Publicado: (2022)

Targeting bone metastases starting from the preneoplastic niche: home sweet home
por: Santini, Daniele, et al.
Publicado: (2011)

Classic Kaposi Sarcoma: to treat or not to treat?
por: Vincenzi, Bruno, et al.
Publicado: (2015)

Erythema nodosum: what should we consider about it?
por: Babamahmoudi, Farhang, et al.
Publicado: (2016)

Diagnosis of coronavirus disease 2019 pneumonia in pregnant women: can we rely on lung ultrasound?
por: Sperandeo, Marco, et al.
Publicado: (2020)

Coronavirus disease 2019 pandemic: should we delay cartilage regenerative procedures and accept the consequences, or can we find a new normality?
por: Vannini, Francesca, et al.
Publicado: (2020)

Rapidly organize redeployed medical staff in coronavirus disease 2019 pandemic: what we should do
por: Meng, Mei, et al.
Publicado: (2020)

Phase I study of intermittent and chronomodulated oral therapy with capecitabine in patients with advanced and/or metastatic cancer
por: Santini, Daniele, et al.
Publicado: (2006)

Evidence-based guidelines: Improving AGREEment on consistence evaluation
por: Vincenzi, Bruno, et al.
Publicado: (2012)

Coronavirus disease 2019: What we know?
por: He, Feng, et al.
Publicado: (2020)

2019 Novel coronavirus: where we are and what we know
por: Cheng, Zhangkai J., et al.
Publicado: (2020)

Should We Treat Prehypertension in Diabetes?: What are the cons?
por: Grossman, Ehud
Publicado: (2009)

COVID‐19 coagulopathy – what should we treat?
por: Chowdary, Pratima
Publicado: (2022)

What is the optimal usage of coronavirus disease 2019 convalescent plasma donations?
por: Focosi, Daniele, et al.
Publicado: (2021)

In reply: efficacy of a new videolaryngoscope; what we should assess?
por: Asai, Takashi, et al.
Publicado: (2012)

Autonomous Sensory Meridian Response: What is It? and Why Should We Care?
por: Lloyd, James V., et al.
Publicado: (2017)

What Should We Do to Help Lessen Older Patients’ Pain?
por: Kim, Sun-Wook
Publicado: (2020)

Prescribing COVID-19 treatments: what we should never forget
por: Tunesi, S., et al.
Publicado: (2020)

MicroRNAs and Bone Metastasis: A New Challenge
por: Croset, Martine, et al.
Publicado: (2014)

Extensive plasma proteomic profiling revealed receptor activator of nuclear factor kappa-Β ligand (RANKL) as emerging biomarker of nivolumab clinical benefit in patients with metastatic renal cell carcinoma
por: Simonetti, Sonia, et al.
Publicado: (2022)

Eyelid Lentigo Maligna Treated With Imiquimod 5%: Should We Fear of Ocular Side Effects?
por: Conforti, Claudio, et al.
Publicado: (2023)

Bradycardia and coronavirus disease 2019: What is behind?
por: Barkas, Fotios, et al.
Publicado: (2021)

Correction to: 2019 Novel coronavirus: where we are and what we know
por: Cheng, Zhangkai J., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_egidur60p5mj2gmlc0na8oughl